In a report released today, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Compass Therapeutics (CMPX – Research Report), with a price target of $10.00. The company’s shares opened today at $3.01.
According to TipRanks, Pantginis is an analyst with an average return of -6.3% and a 33.60% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Clene, Actinium Pharmaceuticals, and Tempest Therapeutics.
Compass Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $9.67, representing a 221.26% upside. In a report released on April 20, Wedbush also maintained a Buy rating on the stock with a $8.00 price target.
See the top stocks recommended by analysts >>
The company has a one-year high of $5.65 and a one-year low of $1.36. Currently, Compass Therapeutics has an average volume of 369.6K.
Based on the recent corporate insider activity of 31 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of CMPX in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Compass Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is developing proprietary antibody therapeutics intended to engage the immune system to treat both solid tumors and hematological malignancies. Its pipeline product candidates are CTX-471/ CD137 agonist and CTX-8371.
Read More on CMPX:
- Compass Therapeutics Reports First Quarter Financial Results and Provides Corporate Update
- Compass Therapeutics removed from Best Ideas List at Wedbush
- Compass Therapeutics to Participate in the Stifel 2023 Virtual Targeted Oncology Days
- Compass Therapeutics to Participate in the Cantor Fitzgerald Future of Oncology Symposium
- Compass Therapeutics expects cash to fund operations into 2026
